Acetyllevocarnitine Hydrochloride Tablets + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Diabetic Peripheral Neuropathy (DPN)

Conditions

Diabetic Peripheral Neuropathy (DPN), Paresthesia

Trial Timeline

Jul 23, 2020 → Jan 25, 2022

NCT ID

NCT05319275

About Acetyllevocarnitine Hydrochloride Tablets + Placebo

Acetyllevocarnitine Hydrochloride Tablets + Placebo is a phase 3 stage product being developed by Haisco Pharmaceutical Group for Diabetic Peripheral Neuropathy (DPN). The current trial status is completed. This product is registered under clinical trial identifier NCT05319275. Target conditions include Diabetic Peripheral Neuropathy (DPN), Paresthesia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05319275	Phase 3	Completed	Jul 23, 2020	Jan 25, 2022	Diabetic Peripheral Neuropathy (DPN)

Competing Products

20 competing products in Diabetic Peripheral Neuropathy (DPN)

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	44
CHF6467 active	Comac Medical	Phase 1/2	33
Ruboxistaurin mesylate	Eli Lilly	Phase 3	77
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	47
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	28
Baricitinib + Placebo	Eli Lilly	Phase 2	52
LY3857210 + Placebo	Eli Lilly	Phase 2	52
UBX1325	Unity Biotechnology	Phase 2	44
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	44
UBX1325	Unity Biotechnology	Phase 1	25
CT-P42 + Eylea	Celltrion	Phase 3	77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	85
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	85
CS-3150 + placebo	Daiichi Sankyo	Phase 2	52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	52
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	77
DS-5565 + placebo	Daiichi Sankyo	Phase 3	77
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	77
DS-5565	Daiichi Sankyo	Phase 3	77
Beraprost sodium	Astellas Pharma	Pre-clinical	23

Other Products from Haisco Pharmaceutical Group

Crisugabalin + PlaceboApproved

Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDApproved

Cyclopofol + PropofolApproved

Ciprofol + PropofolApproved

CipepofolApproved